References
- Vega F, Medeiros LJ, Bueso-Romos CE, et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015;144(3):377–392.
- Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
- Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long terum remissions with imatinib. Blood. 2014;123(23):3574–3577.
- Arefi M, Garcia JL, Penarrubia MJ, et al. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PGDGFRB rearrangement. Eur J Haematol. 2012;89(1):37–41.
- Jawhar W, Naumann N, Schwaab J, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96(9):1463–1470.
- Shimomura Y, Maruoka H, Ishikawa T. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia. Int J Hematol. 2017;105(5):697–701.
- Gorello P, La Starza R, Brandimarte L, et al. A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene. Leukemia. 2008;22(1):216–218.
- Greipp PT, Dewald GW, Tefferi A. prevalence, breakpoint distribution, and clinical correlates of t (5;12). Cancer Genet Cytogen. 2004; 153(2):170–172.
- Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7):481–487.
- Bohmer FD, Karagyozov L, Uecker A, et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site Inhibitor STI-571. J Biol Chem. 2003;278(7):5148–5155.
- Baygazov K, Kastner R, Gorna M, et al. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors. Leukemia. 2017;31(1):237–240.
- Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198–e206.
- Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362(4):369–370.